Filing Details

Accession Number:
0000874015-18-000007
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-01-02 20:49:55
Reporting Period:
2018-01-01
Accepted Time:
2018-01-02 20:49:55
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874015 Ionis Pharmaceuticals Inc IONS Pharmaceutical Preparations (2834) 330336973
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1537529 P Brett Monia C/O Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad CA 92010
Svp, Antisense Drug Discovery No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-01-01 156 $42.76 11,782 No 5 J Direct
Common Stock Disposition 2018-01-02 163 $50.00 11,619 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 J Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Acquisiton 2018-01-02 58,125 $0.00 58,125 $49.25
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
58,125 2019-01-02 2025-01-01 No 4 A Direct
Footnotes
  1. Reporting 156 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 156 shares may not be sold until July 2, 2018.
  2. Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 14,531 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.
  3. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 7/31/2014.